Literature DB >> 18363886

Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS).

Evanthia Diamanti-Kandarakis1, Ilias Katsikis, Christina Piperi, Eleni Kandaraki, Athanasia Piouka, Athanasios G Papavassiliou, Dimitrios Panidis.   

Abstract

BACKGROUND: Nonenzymatic advanced glycation and oxidation end-products, advanced glycation end-products (AGEs), impart a potent impact on vessels and other tissues in diabetic state and in euglycaemic conditions with increased oxidative stress. Insulin resistant (IR) polycystic ovary syndrome (PCOS) women, have elevated serum AGEs, increased receptor (RAGE) expression, and increased deposition with differential localization in the polycystic ovarian tissue (theca and granulosa) compared to normal.
OBJECTIVE: To determine whether the raised AGE levels in noninsulin resistant women with PCOS is a distinct finding compared with those presenting the isolated components of the syndrome and among PCOS subphenotypes. Noninsulin resistant women were selected in order to show that serum AGEs are elevated in PCOS independently of the presence of IR.
DESIGN: Clinical trial. PATIENTS: One hundred and ninety-three age- and BMI-matched young lean noninsulin resistant women were studied. Among them, 100 women were diagnosed with PCOS according to Rotterdam criteria, and divided to subphenotypes (hyperandrogenaemia with or without PCO morphology and with or without anovulation). Sixty-eight women with the isolated components of the PCOS phenotype were also studied along with 25 healthy women. MEASUREMENTS: Serum AGE levels, metabolic, hormonal profiles and intravaginal ultrasound were determined in all subjects.
RESULTS: The studied population did not differ in BMI, fasting insulin concentration, waist : hip and glucose : insulin ratios. PCOS women exhibited statistically higher AGEs levels (7.96 +/- 1.87 U/ml, P < 0.001) compared with those with isolated hyperandrogenaemia (5.61 +/- 0.61 U/ml), anovulation (5.53 +/- 1.06 U/ml), US-PCO morphology (5.26 +/- 0.25 U/ml) and controls (5.86 +/- 0.89 U/ml).
CONCLUSIONS: In PCOS, serum AGEs are distinctly elevated compared with women having the isolated characteristics of the syndrome. No difference was observed between PCOS subphenotypes. As chronic inflammation and increased oxidant stress have been incriminated in the pathophysiology of PCOS, the role of AGEs as inflammatory and oxidant mediators, may be linked with the metabolic and reproductive abnormalities of the syndrome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18363886     DOI: 10.1111/j.1365-2265.2008.03247.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  41 in total

Review 1.  Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome.

Authors:  Selma F Witchel; Sergio E Recabarren; Frank González; Evanthia Diamanti-Kandarakis; Kai I Cheang; Antoni J Duleba; Richard S Legro; Roy Homburg; Renato Pasquali; Rogerio A Lobo; Christos C Zouboulis; Fahrettin Kelestimur; Franca Fruzzetti; Walter Futterweit; Robert J Norman; David H Abbott
Journal:  Endocrine       Date:  2012-06-04       Impact factor: 3.633

Review 2.  Glycation and insulin resistance: novel mechanisms and unique targets?

Authors:  Fei Song; Ann Marie Schmidt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-08       Impact factor: 8.311

3.  Advanced glycation end products interfere in luteinizing hormone and follicle stimulating hormone signaling in human granulosa KGN cells.

Authors:  Eleni A Kandaraki; Antonios Chatzigeorgiou; Efstathia Papageorgiou; Christina Piperi; Christos Adamopoulos; Athanasios G Papavassiliou; Michael Koutsilieris; Evanthia Diamanti-Kandarakis
Journal:  Exp Biol Med (Maywood)       Date:  2017-09-15

Review 4.  Medical management of metabolic dysfunction in PCOS.

Authors:  Antoni J Duleba
Journal:  Steroids       Date:  2011-12-13       Impact factor: 2.668

5.  Advanced Glycation End Products: Building on the Concept of the "Common Soil" in Metabolic Disease.

Authors:  Henry H Ruiz; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Endocrinology       Date:  2020-01-01       Impact factor: 4.736

6.  The effects of old, new and emerging medicines on metabolic aberrations in PCOS.

Authors:  Alexandra Bargiota; Evanthia Diamanti-Kandarakis
Journal:  Ther Adv Endocrinol Metab       Date:  2012-02       Impact factor: 3.565

7.  Aspects of Cardiometabolic Risk in Women with Polycystic Ovary Syndrome.

Authors:  Thomas S Paterakis; Evanthia Diamanti-Kandarakis
Journal:  Curr Obes Rep       Date:  2014-12

Review 8.  Cardiovascular risk factors and events in women with androgen excess.

Authors:  D Macut; I B Antić; J Bjekić-Macut
Journal:  J Endocrinol Invest       Date:  2014-11-29       Impact factor: 4.256

9.  Is PCOS an inflammatory process?

Authors:  Antoni J Duleba; Anuja Dokras
Journal:  Fertil Steril       Date:  2012-01       Impact factor: 7.329

Review 10.  PCOS Forum: research in polycystic ovary syndrome today and tomorrow.

Authors:  Renato Pasquali; Elisabet Stener-Victorin; Bulent O Yildiz; Antoni J Duleba; Kathleen Hoeger; Helen Mason; Roy Homburg; Theresa Hickey; Steve Franks; Juha S Tapanainen; Adam Balen; David H Abbott; Evanthia Diamanti-Kandarakis; Richard S Legro
Journal:  Clin Endocrinol (Oxf)       Date:  2011-04       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.